EDIT Insider Trading

Insider Ownership Percentage: 1.90%
Insider Buying (Last 12 Months): $253,800.00
Insider Selling (Last 12 Months): $180,348.49

Editas Medicine Insider Trading History Chart

This chart shows the insider buying and selling history at Editas Medicine by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Editas Medicine Share Price & Price History

Current Price: $1.15
Price Change: Price Decrease of -0.015 (-1.29%)
As of 04/1/2025 04:40 PM ET

This chart shows the closing price history over time for EDIT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.16Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Editas Medicine (NASDAQ:EDIT)

71.90% of Editas Medicine stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EDIT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$8.44Mbought$2.53MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal InflowsTotal Outflows
Editas Medicine logo
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Read More on Editas Medicine

Today's Range

Now: $1.15
Low: $1.12
High: $1.18

50 Day Range

MA: $1.51
Low: $1.16
High: $3.20

52 Week Range

Now: $1.15
Low: $1.12
High: $7.41

Volume

1,610,132 shs

Average Volume

2,542,744 shs

Market Capitalization

$95.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Who are the company insiders with the largest holdings of Editas Medicine?

Editas Medicine's top insider investors include:
  1. Gilmore Neil O'neill (CEO)
  2. Baisong Mei (SVP)
  3. Baisong Mei (EVP)
  4. Michelle Robertson (CFO)
  5. Bruce Eaton (EVP)
  6. Linda Burkly (EVP)
  7. Jessica Hopfield (Director)
Learn More about top insider investors at Editas Medicine.